Neurokinin 3 (NK3) antagonists are a new class of medications designed to manage vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. Unlike hormone therapy, NK3 antagonists work by modulating the neurokinin-3 receptors involved in the body’s thermoregulation, offering an alternative for patients who cannot or prefer not to use estrogen-based treatments.
Why It Matters
VMS affects up to 80% of women during menopause and can significantly impact sleep, mood, and overall quality of life. While hormone therapy remains effective for many, some patients face contraindications such as a history of hormone-sensitive cancers, cardiovascular risk, or personal preference to avoid hormones. NK3 antagonists provide a non-hormonal option to address these symptoms effectively.
How Clinicians Can Implement Them
Practical considerations for prescribing NK3 antagonists include:
- Dosing and titration: Start at the recommended dose and adjust based on symptom control and tolerability.
- Monitoring and side effects: Common side effects may include headache or mild gastrointestinal symptoms. Liver function tests are recommended for some agents.
- Patient counseling: Discuss expected symptom improvement, potential side effects, and realistic timelines to set expectations.
- Clinical decision-making: Evaluate patient history, comorbidities, and preferences to determine if NK3 antagonists are appropriate.
Integrating NK3 antagonists into practice allows clinicians to expand treatment options, address unmet patient needs, and provide personalized care for women navigating menopause.
For clinicians seeking practical guidance on dosing, monitoring, and patient counseling, the 30-minute accredited program “Implementing NK3 Antagonists in Clinical Practice” provides case-based insights and evidence-based strategies to confidently introduce this therapy into your practice.
This program has received an unrestricted educational grant or in-kind support from Astellas Pharma Canada Inc.